All In Biotech

Drug Trial Radar · NCT06307522

MRG-001 in Patients With Alcoholic Hepatitis

An Open-Label, Dose-Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MRG-001 in Patients With Alcoholic Hepatitis

Last checked: Nov 20, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Sep 1, 2024

Primary completion

Sep 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
MedRegen LLCIndustry
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH).

Conditions

  • Alcoholic Hepatitis
  • Acute Alcoholic Hepatitis

Interventions

  • MRG-001Drug

    Patients will receive subcutaneous administration of MRG-001 at designated visits.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of Treatment-Emergent Adverse EventsTime frame: 28 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.